Novella Clinical Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Morrisville NC United States (1998)
Status: Acquired by IQVIA (2013)

Organization Overview

First Clinical Trial
2013
NCT01880840
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Novella Clinical

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Neuroendocrine (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 1)

Colorectal Neoplasms (Phase 1)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Glioblastoma (Phase 3)

Herpes Labialis (Phase 2)

Lung Neoplasms (Phase 1)

Mucositis (Phase 2)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 1)

Psoriasis (Phase 1)

Rhinitis (Phase 4)

Rhinitis, Allergic (Phase 4)

Small Cell Lung Carcinoma (Phase 1)

Stomatitis (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 30
  • # of Trial APIs: 30